Genentech, a member of the Roche Group, achieved positive results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating a combination regimen of pertuzumab and Herceptin (trastuzumab) plus chemotherapy (docetaxel) in women with early-stage, HER2-positive breast cancer. The data showed that the two antibodies plus docetaxel, given prior to surgery, significantly improved the rate of complete tumor disappearance (pathological complete response rate of 45.8%) in the breast by more than ...